Jane E. Tighe
Impact in
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Hematology top 5%
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
Papers in
- Hematology 15
- Multiple Myeloma Research and Treatments 6
- Acute Myeloid Leukemia Research 5
- Chronic Myeloid Leukemia Treatments 3
- Genetics 7
- Chronic Lymphocytic Leukemia Research 7
- Co-authors
- Chris Fegan (3 shared papers)Saad M. B. Rassam (2 shared papers)M.J. Leach (2 shared papers)Andy C. Rawstron (2 shared papers)Peter Hillmen (2 shared papers)Andrew Haynes (2 shared papers)Paul Moreton (2 shared papers)Ben Kennedy (2 shared papers)
- Journals
- British Journal of Haematology (7 papers)Blood (3 papers)Journal of Clinical Oncology (2 papers)Clinical Science (1 paper)Cell Cycle (1 paper)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Jane E. Tighe
23 papers receiving 915 citations
Peers
Comparison fields: 5 of 72
- Genetics 433
- Hematology 342
- Pathology and Forensic Medicine 432
- Immunology 224
- Oncology 237
Countries citing papers authored by Jane E. Tighe
This map shows the geographic impact of Jane E. Tighe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane E. Tighe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane E. Tighe more than expected).
Fields of papers citing papers by Jane E. Tighe
This network shows the impact of papers produced by Jane E. Tighe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane E. Tighe. The network helps show where Jane E. Tighe may publish in the future.
Co-authors
The 25 scholars most cited alongside Jane E. Tighe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 329 | |
| 2 | 2004 | 244 | |
| 3 | 2010 | 87 | |
| 4 | 2007 | 72 | |
| 5 | 2007 | 39 | |
| 6 | 2024 | 27 | |
| 7 | 2015 | 22 | |
| 8 | 2020 | 22 | |
| 9 | 2003 | 21 | |
| 10 | 2003 | 15 | |
| 11 | 1995 | 14 | |
| 12 | 2013 | 8 | |
| 13 | 2011 | 7 | |
| 14 | A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study. | 2003 | 6 |
| 15 | 2000 | 6 | |
| 16 | 2011 | 6 | |
| 17 | 2007 | 6 | |
| 18 | 2020 | 5 | |
| 19 | 2014 | 4 | |
| 20 | 2022 | 3 |
About Jane E. Tighe
Jane E. Tighe is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 24 papers that have together received 948 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (7 papers), Multiple Myeloma Research and Treatments (6 papers), Acute Myeloid Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Peptidase Inhibition and Analysis (4 papers), Protein Degradation and Inhibitors (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Protease and Inhibitor Mechanisms (2 papers). The work is most often cited by research in Genetics (433 citations), Hematology (342 citations), Pathology and Forensic Medicine (432 citations), Immunology (224 citations) and Oncology (237 citations). Jane E. Tighe has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Chris Fegan, Saad M. B. Rassam, M.J. Leach, Andy C. Rawstron, Peter Hillmen, Andrew Haynes, Paul Moreton, Ben Kennedy, Guy S. Lucas and David Graham Oscier. Their work appears in journals such as British Journal of Haematology, Blood, Journal of Clinical Oncology, Clinical Science and Cell Cycle.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.